BIND Therapeutics Inc (NASDAQ: BIND) +42% - Provided clinical update for BIND-014.
Biodel Inc (NASDAQ: BIOD) +38% - Reported positive preliminary results from Phase 2a clinical trial of BIOD-531.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) +27% - Announced positive Phase 3 study results in cooperation with AbbVie.
NephroGenex Inc (NASDAQ: NRX) +17% - The company received positive advice from the European Medicines Agency Regarding its Phase 3 program with Pyridorin.
Protalix Bio Therapeutics Inc. (NYSE: PLX) +11% - Announced interim efficacy for PRX-102 trial.
Amicus Therapeutics, Inc. (NASDAQ: FOLD) +10% - Reported additional favorable data on cardiac endpoint.
Aeropostale Inc (NYSE: ARO) +6% - Raised Q4 EPS guidance.
Infinity Pharmaceuticals Inc. (NASDAQ: INFI) -13% - Reported that its Phase 2 study of Duvelisib did not meet primary endpoint.
GW Pharmaceuticals PLC ADR (NASDAQ: GWPH) -3% - Announced negative results from Sativex Phase 3 cancer pain trials.
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) -4% - Late Wednesday, the company provided an update on Phase 2 clinical trial with Eculizumab.
AmTrust Financial Services Inc (NASDAQ: AFSI) - 4.7% - Announced a three million share offering.
See more from Benzinga
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.